|1.||Knudsen, Gitte M: 11 articles (06/2015 - 09/2005)|
|2.||Hamon, Michel: 7 articles (11/2008 - 05/2002)|
|3.||Dean, Brian: 5 articles (06/2014 - 12/2004)|
|4.||Marin, Philippe: 5 articles (05/2014 - 08/2010)|
|5.||Frokjaer, Vibe G: 5 articles (03/2012 - 03/2008)|
|6.||Svarer, Claus: 5 articles (01/2010 - 09/2005)|
|7.||Knudsen, G M: 4 articles (04/2015 - 03/2008)|
|8.||Courteix, Christine: 4 articles (10/2013 - 08/2010)|
|9.||Audenaert, Kurt: 4 articles (01/2012 - 02/2003)|
|10.||Vaillancourt, C: 4 articles (12/2011 - 07/2005)|
|1.||Schizophrenia (Dementia Praecox)
01/01/1995 - "The limited clinical evidence available also suggests that compounds producing 5-HT2A receptor blockade are effective, in particular, against the negative symptoms of schizophrenia."
12/01/2013 - "In conclusion, our results do not support the hypothesis that the T102C and 1438 A/G polymorphisms in the 5-HT2A receptor gene are associated with schizophrenia, but further studies in a larger sample are needed."
12/01/2013 - "The aim of this study is to investigate whether there were any associations between the T102C and 1438 A/G polymorphisms of the 5-HT2A receptor gene and schizophrenia. "
07/30/2013 - "We hypothesize that the 5-HT2A receptor gene is a modifier gene of schizophrenia and suggest that additional studies are warranted. "
09/01/2011 - "Three previous 5-HT(2A) receptor antagonists have been discontinued after Phase II or III trials, and available Phase IIa data on the remaining 5-HT(2A) receptor antagonist will need substantial additional validation to be approved as a new treatment strategy against schizophrenia."
03/15/2015 - "However, the efficacy of a 5-HT2A receptor antagonist for pain relief in this situation and the mechanism remain unknown. "
02/01/2011 - "However, we find that recent pre-clinical findings highlight the potential of peripherally acting 5-HT(1) and 5-HT(2A) receptor agonists and centrally penetrating 5-HT(7) receptor agonists to reduce chronic pain. "
09/01/2002 - "5-HT2A receptor subtype in the peripheral branch of sensory fibers is involved in the potentiation of inflammatory pain in rats."
09/01/2001 - "[Involvement of peripheral 5-HT2A receptor activation in inflammatory pain]."
05/04/2001 - "This result suggested that the synthesis of 5-HT2A receptor is enhanced in spinal dorsal horn, NRM, vlPAG and DRN during inflammatory pain."
|3.||Parkinson Disease (Parkinson's Disease)
03/01/2015 - "Pimavanserin is a selective serotonin 2A receptor (5-HT2AR) inverse agonist that has shown promise for treatment of psychotic symptoms in patients with Parkinson's disease. "
01/01/2014 - "Changes in 5-HT2A receptor expression in untreated, de novo patients with Parkinson's disease."
01/01/2012 - "To determine the role of a serotonin 2A receptor gene (=HTR2A) variant in the development of impulse control and repetitive behaviors in Parkinson's disease. "
07/01/2010 - "These data suggest that 5-HT(2A) receptor antagonists may represent a novel approach to ameliorate motor symptoms of Parkinson's disease."
04/01/2010 - "To examine for the first time in vivo changes in serotonin 2A receptor neurotransmission among patients having Parkinson disease (PD) with VHs. "
|4.||Alzheimer Disease (Alzheimer's Disease)
08/01/2012 - "Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease."
01/01/2009 - "Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study."
12/01/2006 - "No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease."
11/01/2004 - "5-HT2A receptor polymorphism may modulate antipsychotic treatment response in Alzheimer's disease."
08/01/2004 - "The 5-HT2A receptor polymorphism may contribute to the expression of psychosis and agitation/aggression in patients with Alzheimer disease. "
05/01/2006 - "Peripheral 5-HT2A receptor antagonism attenuates primary thermal hyperalgesia and secondary mechanical allodynia after thermal injury in rats."
10/18/2013 - "Disrupting the interaction between the PDZ protein PSD-95 and the C-terminal domain of the 5-HT2A serotonin receptor has been shown to reduce hyperalgesia in a rodent model of neuropathic pain. "
08/01/2010 - "Disrupting 5-HT(2A) receptor/PDZ protein interactions reduces hyperalgesia and enhances SSRI efficacy in neuropathic pain."
06/01/1998 - "These findings strongly suggest that the 5-HT2A receptor subtype, but not the 5-HT3 subtype, is involved in 5-HT-induced hyperalgesia in acute injury and inflammation in the rat. "
05/01/2006 - "The present study examined the effect of a selective 5-HT2A receptor antagonist, sarpogrelate, on hyperalgesia and allodynia induced by thermal injury in rats. "
|1.||Serotonin (5 Hydroxytryptamine)
|3.||Risperidone (Risperdal Consta)
|5.||Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)
|7.||Antipsychotic Agents (Antipsychotics)
|9.||Proteins (Proteins, Gene)
|4.||Drug Therapy (Chemotherapy)